Guideline-Directed Medical Therapy in Heart Failure Management

Guideline-Directed Medical Therapy (GDMT) represents a structured approach to pharmacological management in patients with heart failure, integrating agents that modulate neurohormonal pathways and improve haemodynamic stability. Central to this strategy are inhibitors of the renin–angiotensin–aldosterone system, beta-adrenergic blockers, mineralocorticoid receptor antagonists and sodium–glucose cotransporter 2 inhibitors, together with angiotensin receptor–neprilysin inhibitors in suitable candidates. By attenuating maladaptive neurohormonal activation, these therapies reduce ventricular remodelling, lower rates of hospitalisation and extend survival. Implementation of GDMT across the spectrum of left ventricular dysfunction—from acute decompensation to chronic stable disease—requires careful dose titration and monitoring of blood pressure, renal function and electrolytes. Despite robust evidence, real-world adherence and optimisation frequently fall short of target doses, owing to hypotension, renal impairment or patient comorbidities. Recent advances emphasise rapid initiation and uptitration during hospitalisation for acute heart failure and strategies to overcome barriers to full-dose therapy in elderly or frail populations. The global significance of GDMT lies in its potential to transform outcomes at scale, support remission of heart failure symptoms and guide integrated care pathways that link inpatient stabilisation with community-based follow-up.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Guideline-Directed Medical Therapy in Heart Failure Management publication trend

The graph below shows the total number of articles in guideline-directed medical therapy in heart failure management across all publications each year (not limited to Nature Index journals).

Technical terms

Guideline-Directed Medical Therapy (GDMT): A prescribed regimen of heart failure medications based on international guidelines to improve survival and reduce hospitalisation.

Ejection Fraction: The proportion of blood ejected from the left ventricle with each contraction, used to classify heart failure as reduced or preserved.

Neurohormonal blockade: Pharmacological inhibition of compensatory hormonal systems—such as the renin–angiotensin–aldosterone system and sympathetic nervous system—that contribute to heart failure progression.

References

1. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial. Journal of Cardiac Failure (2023).
2. Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion. Frontiers in Cardiovascular Medicine (2023).